5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide has been researched along with naloxone in 3 studies
| Studies (5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide) | Trials (5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide) | Recent Studies (post-2010) (5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide) | Studies (naloxone) | Trials (naloxone) | Recent Studies (post-2010) (naloxone) |
|---|---|---|---|---|---|
| 73 | 0 | 8 | 20,134 | 1,257 | 3,321 |
| Protein | Taxonomy | 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide (IC50) | naloxone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.043 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0219 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0397 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1896 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.05 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0795 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0154 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0089 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.0055 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhalla, S; Gulati, A; Matwyshyn, G | 2 |
| Bhalla, S; Gulati, A; Rapolaviciute, V | 1 |
3 other study(ies) available for 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and naloxone
| Article | Year |
|---|---|
A novel combination of opiates and endothelin antagonists to manage pain without any tolerance development.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Dansyl Compounds; Disease Models, Animal; Drug Therapy, Combination; Drug Tolerance; Endothelin A Receptor Antagonists; Guanosine 5'-O-(3-Thiotriphosphate); Injections, Intraventricular; Male; Mice; Morphine; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Peptides, Cyclic; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptors, Opioid, mu; Sulfur Radioisotopes; Time Factors | 2004 |
Morphine tolerance does not develop in mice treated with endothelin-A receptor antagonists.
Topics: Analgesics, Opioid; Animals; Dansyl Compounds; Drug Interactions; Drug Tolerance; Endothelin A Receptor Antagonists; Injections, Intraventricular; Male; Mice; Morphine; Naloxone; Pain Threshold; Peptides, Cyclic; Receptor, Endothelin A; Receptors, Opioid | 2005 |
Determination of α(2)-adrenoceptor and imidazoline receptor involvement in augmentation of morphine and oxycodone analgesia by agmatine and BMS182874.
Topics: Agmatine; Analgesics; Animals; Dansyl Compounds; Drug Synergism; Idazoxan; Imidazoline Receptors; Male; Mice; Morphine; Naloxone; Oxycodone; Receptors, Adrenergic, alpha-2; Receptors, Endothelin; Yohimbine | 2011 |